[Federal Register Volume 83, Number 38 (Monday, February 26, 2018)]
[Notices]
[Pages 8288-8289]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-03812]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Service Administration
Advisory Commission on Childhood Vaccines
AGENCY: Health Resources and Service Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, notice
is hereby given that a meeting is scheduled for the Advisory Commission
on Childhood Vaccines (ACCV). This meeting will be open to the public.
Information about the ACCV and the agenda for this meeting can be
obtained by accessing the following website: http://www.hrsa.gov/advisorycommittees/childhoodvaccines/index.html.
DATES: The meeting will be held on March 8, 2018, at 10:00 a.m. ET.
ADDRESSES: This meeting will be held via Adobe Connect meeting and
conference call. This is not an in-person meeting. The public can join
the meeting by:
1. (Audio Portion) Calling the conference phone number (800) 988-
0218 and providing the following information:
Leader Name: Dr. Narayan Nair.
Password: 9302948.
2. (Visual Portion) Connecting to the ACCV Adobe Connect Meeting
using the following URL: https://hrsa.connectsolutions.com/accv/.
Participants should call and connect 15 minutes prior to the meeting in
order for logistics to be set up. If you have never attended an Adobe
Connect meeting, please test your connection using the following URL:
https://hrsa.connectsolutions.com/common/help/en/support/meeting_test.htm and get a quick overview by following URL: http://www.adobe.com/go/connectpro_overview.
[[Page 8289]]
FOR FURTHER INFORMATION CONTACT: Anyone requesting information
regarding the ACCV should contact Annie Herzog, Program Analyst,
Division of Injury Compensation Programs (DICP), HRSA in one of three
ways: (1) Send a request to the following address: Annie Herzog,
Program Analyst, DICP, HRSA, 5600 Fishers Lane, 08N146B, Rockville,
Maryland 20857; (2) call (301) 443-6593; or (3) send an email to
[email protected].
The ACCV will meet on Thursday, March 8, 2018, beginning at 10:00
a.m. via Adobe Connect Meeting; however, meeting times and information
to join the meeting and/or conference call could change. For the latest
information regarding meeting start time and information to join the
meeting and/or conference call, please check the ACCV website: http://www.hrsa.gov/advisorycommittees/childhoodvaccines/index.html.
SUPPLEMENTARY INFORMATION: The ACCV was established by section 2119 of
the Public Health Service Act (the Act) (42 U.S.C. 300aa-19), as
enacted by Public Law (Pub. L.) 99-660, and as subsequently amended,
and advises the Secretary of HHS (the Secretary) on issues related to
implementation of the National Vaccine Injury Compensation Program
(VICP).
Other activities of the ACCV include: Recommending changes to the
Vaccine Injury Table at its own initiative or as the result of the
filing of a petition; advising the Secretary in implementing section
2127 of the Act regarding the need for childhood vaccination products
that result in fewer or no significant adverse reactions; surveying
federal, state, and local programs and activities related to gathering
information on injuries associated with the administration of childhood
vaccines, including the adverse reaction reporting requirements of
section 2125(b) of the Act; advising the Secretary on the methods of
obtaining, compiling, publishing, and using credible data related to
the frequency and severity of adverse reactions associated with
childhood vaccines; consulting on the development or revision of
Vaccine Information Statements; and, recommending to the Director of
the National Vaccine Program research related to vaccine injuries which
should be conducted to carry out the VICP.
The agenda items for the March 8, 2018, meeting will include, but
are not limited to, updates from DICP, Department of Justice (DOJ),
National Vaccine Program Office (NVPO), Immunization Safety Office
(Centers for Disease Control and Prevention), National Institute of
Allergy and Infectious Diseases (National Institutes of Health) and
Center for Biologics, Evaluation and Research (Food and Drug
Administration). A draft agenda and additional meeting materials will
be posted on the ACCV website: http://www.hrsa.gov/advisorycommittees/childhoodvaccines/index.html prior to the meeting. Agenda items are
subject to change as priorities dictate.
Members of the public will have the opportunity to provide
comments. Oral comments will be honored in the order they are requested
and may be limited as time allows. Requests to make oral comments or
provide written comments to the ACCV should be sent to Annie Herzog by
March 5, 2018, using the address and phone number above. Individuals
who plan to participate and need special assistance, such as sign
language interpretation or other reasonable accommodations, should
notify Annie Herzog, using the address and phone number above at least
10 days prior to the meeting.
Amy McNulty,
Acting Director, Division of the Executive Secretariat.
[FR Doc. 2018-03812 Filed 2-23-18; 8:45 am]
BILLING CODE 4165-15-P